Editor’s Note: Former tech executive Jeff Brown has predicted some of the biggest tech paradigm shifts of the past two decades — including the rise of Bitcoin, Nvidia, and self-driving cars — giving his readers a chance to turn $1k into almost half a million, $277,000, and $22,500. He’s now predicting a major paradigm shift in the U.S. dollar. Click here for the details or read more below.
Dear Reader,
Is it time to say goodbye to the old U.S. dollar?
President Trump just signed a game-changing law…
That could soon upgrade the U.S. dollar in checking and savings accounts…
President Trump himself called this new initiative a “big innovation”...
And said that this new type of currency represents “American brilliance at its best.”
No wonder Chase, Bank of America, Citigroup, Wells Fargo, and U.S. Bancorp…
Are already preparing for what could be the biggest change to our financial system in 54 years.
According to recent congressional hearings…
The market for “Trump’s new dollar” could see growth of up to 1,900% by 2030.
That’s enough to grow a $10k investment into $200,000.
With this new law establishing this new currency as a legal form of payment…
I believe adoption is about to go through the roof.
Click here to get the details because…
Billionaire venture capitalist Chamath Palihapitiya predicted that the size of this market could “quadruple or quintuple” by the end of the year.
We have so much to look forward to,
Jeff Brown
Founder & CEO, Brownstone Research
Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare Stocks
Written by Thomas Hughes. Published 8/19/2025.
Key Points
- Eli Lilly insiders bought in August, highlighting a value opportunity in a blue-chip healthcare stock.
- Teleflex insiders bought in August, a move compounded by institutions.
- CalciMedica insiders bought in August, but investors should be wary; dilution is a real threat that will emerge in 2026.
Insiders are buying healthcare companies in 2025, with a notable uptick in Q3.
The stocks featured here offer value—often deep value—relative to prior trading levels, but the question remains: are they good buys for investors? This article examines Eli Lilly (NYSE: LLY), Teleflex (NYSE: TFX), and Calcimedica (NASDAQ: CALC) to see who's buying, how much, and what investors might expect from their stock prices as the year progresses.
Eli Lilly Faces Competition for Its GLP-1 Sales
I was reviewing your account this morning and... (Ad)
Your account is not currently signed up for MarketBeat's free Monday morning stock ideas. Our team is going to be releasing an important pick on Monday morning (at 11am ET) and we want to make sure that you are able to see it.
Add your name to the distribution list hereIn 2025, Eli Lilly's biggest challenge is slower GLP-1 sales as competition intensifies. On the bright side, the share price is off its early-year highs—and insiders are seizing the opportunity.
InsiderTrades records five purchases by five insiders—including the CEO, an EVP, and three directors—demonstrating strong confidence in Lilly's value. Notably, there was no insider buying over the prior two years, only periodic selling under pre-set plans, tax obligations, or other compensation needs.
Institutions, which own over 80% of the stock, have been net sellers in early Q3, pressuring the share price. If that trend continues, upside may be limited. However, analyst coverage is expanding, ratings remain favorable, and the August consensus projects roughly 35% upside. Other reasons to consider LLY as a buy include its blue-chip status, robust pipeline of new treatments, and healthy balance sheet.
Teleflex Set to Begin Recovery, Accelerates Outlook With Acquisition
Teleflex, a medical products firm, has seen its stock pressured by post-COVID normalization and divestitures. In 2025, though, the company appears on track for renewed growth, bolstered by a recent acquisition. Insiders underscore this opportunity, with five executives buying shares in August.
The August purchases—by four directors and the CEO—represent the first insider buys in years. Institutions, which hold about 95% of the float, also turned net buyers in early Q3, potentially providing a tailwind for future price action.
Analyst sentiment remains subdued, with ratings downgrades and lowering price targets still in effect as of mid-August. Yet the market has overshot to the downside, pushing the stock below analysts' low-end targets—suggesting deep value and significant rebound potential.
The upcoming Q3 report could serve as a catalyst: management has raised guidance above consensus, and the integration of new assets may drive outperformance.
CalciMedica: Beware of Dilution
CalciMedica is a clinical-stage biopharma advancing both existing and new pipeline candidates. In 2025, its stock has been buoyed by positive trial data and multiple insider purchases by the CEO, directors, and other executives.
Insiders now hold over 40% of shares, offering strong support. However, institutions—owning nearly all other shares—have been net sellers in Q3 and may continue until there's more clarity on revenue prospects.
The Q2 report confirmed sufficient runway through mid-2026 but highlighted the limited capital buffer. Without new financing, the company will likely resort to dilutive measures such as share issuances or debt offerings. In Q2, share count rose by 35%, long-term debt ballooned, and shareholder equity was cut by more than 50%.
This email content is a paid advertisement sent on behalf of Brownstone Research, a third-party advertiser of DividendStocks.com and MarketBeat.
If you need help with your newsletter, please feel free to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from DividendStocks.com, you can unsubscribe.
Copyright 2006-2025 MarketBeat Media, LLC.
345 N Reid Place, Sixth Floor, Sioux Falls, South Dakota 57103-7078. U.S.A..
0 Response to "Chase, Bank of America, Wells Fargo Preparing for BIG Change"
Post a Comment